Akrivia Biosciences, a cancer genomics company based in London and Mumbai, announced a foundational scientific breakthrough that uncovers hidden organisation of cancer genomes, successfully decoding breast cancer genomic heterogeneity—a major bottleneck that has historically hindered the comprehensive understanding of tumour biology in patients. The research reveals that tumour mutations are not chaotic, isolated events, but are highly organised into distinct functional programmes that dictate tumour behaviour, survival, and therapeutic resistance.
For years, the sheer complexity and chaotic nature of genomic alterations in cancer have forced precision oncology into a rigid, binary approach of treating isolated mutations. Leveraging this groundbreaking discovery, Akrivia has developed T-OMICS, an extraordinary multi-omics-based framework that solves the ER+/HER2- disease puzzle to a major extent. Akrivia is currently preparing to deploy T-OMICS as a targeted decision-support tool specifically designed to address the unmet needs of the advanced breast cancer patient population.
“Cancer sequencing today generates enormous amounts of data, but clinicians are often left with long lists of mutations and little guidance on how those alterations work together,” said Dr Amit Gupta, Founder of Akrivia. “Our research proves that genomic complexity in breast cancer follows an underlying functional organisation. T-OMICS translates that biology into a clinically actionable framework, directly answering the urgent need for better therapeutic prioritisation.”
The immense clinical utility of the T-OMICS framework is powerfully demonstrated by its ability to resolve the long-standing ambiguity surrounding PIK3CA—one of the most frequently mutated genes in ER+/HER2- breast cancer and a major pharmaceutical drug target.
Historically, clinical trials targeting the PI3K pathway have yielded highly heterogeneous results. Akrivia's research explains why: PIK3CA is not a single biological entity. Its impact is fundamentally dictated by the tumour's broader programmatic context. In some states, a PIK3CA mutation aligns with biologically buffered, slower-growing disease; in others, acting within an aggressive genomic backbone, the exact same mutation requires entirely different therapeutic strategies.
By revealing this context-dependent behaviour, T-OMICS explains why previous targeted drug trials have produced unpredictable responses and offers a clear path forward for patient stratification.
By capturing the complete biological context, T-OMICS provides a transformative framework for the entire oncology ecosystem. For clinicians and molecular tumour boards (MTBs), it enables the confident interpretation of complex sequencing reports, anticipates resistance mechanisms, and helps avoid overtreatment.
For pharmaceutical research, T-OMICS offers a new lens to identify biologically coherent patient subgroups, accurately map therapeutic dependencies, and vastly improve biomarker-guided clinical trial design.
Globally, breast cancer accounts for over 2.3 million new diagnoses each year, with ER+/HER2– representing the most common subtype. While initial therapies are often successful, long-term management of metastatic disease remains severely limited by tumour evolution and therapeutic resistance.
Akrivia is initially deploying the T-OMICS platform to tackle this specific unmet need in metastatic ER+/HER2– breast cancer, with the clear potential to apply these foundational organisational principles across multiple other malignancies in the future.
“Our goal is to build a new generation of precision oncology tools that understand cancer not as isolated lesions, but as dynamic biological systems,” added Dr Gupta. “This is about treating the true tumour programme.”
